JP2013533858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533858A5 JP2013533858A5 JP2013513388A JP2013513388A JP2013533858A5 JP 2013533858 A5 JP2013533858 A5 JP 2013533858A5 JP 2013513388 A JP2013513388 A JP 2013513388A JP 2013513388 A JP2013513388 A JP 2013513388A JP 2013533858 A5 JP2013533858 A5 JP 2013533858A5
- Authority
- JP
- Japan
- Prior art keywords
- tnfα antibody
- use according
- subject
- weeks
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 206010000269 abscess Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 229940127249 oral antibiotic Drugs 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229960002964 adalimumab Drugs 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 210000000106 sweat gland Anatomy 0.000 claims 3
- 238000011287 therapeutic dose Methods 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 206010016717 Fistula Diseases 0.000 claims 1
- 210000003484 anatomy Anatomy 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35112510P | 2010-06-03 | 2010-06-03 | |
| US61/351,125 | 2010-06-03 | ||
| US201161430645P | 2011-01-07 | 2011-01-07 | |
| US61/430,645 | 2011-01-07 | ||
| US201161474764P | 2011-04-13 | 2011-04-13 | |
| US61/474,764 | 2011-04-13 | ||
| PCT/US2011/039135 WO2011153477A2 (en) | 2010-06-03 | 2011-06-03 | Uses and compositions for treatment of hidradenitis suppurativa (hs) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016103023A Division JP2016193916A (ja) | 2010-06-03 | 2016-05-24 | 汗腺膿瘍（ｈｓ）の治療のための使用および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013533858A JP2013533858A (ja) | 2013-08-29 |
| JP2013533858A5 true JP2013533858A5 (enExample) | 2014-07-24 |
| JP5944382B2 JP5944382B2 (ja) | 2016-07-05 |
Family
ID=45064648
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513388A Active JP5944382B2 (ja) | 2010-06-03 | 2011-06-03 | 汗腺膿瘍（ｈｓ）の治療のための使用および組成物 |
| JP2016103023A Pending JP2016193916A (ja) | 2010-06-03 | 2016-05-24 | 汗腺膿瘍（ｈｓ）の治療のための使用および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016103023A Pending JP2016193916A (ja) | 2010-06-03 | 2016-05-24 | 汗腺膿瘍（ｈｓ）の治療のための使用および組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8747854B2 (enExample) |
| EP (1) | EP2575884B1 (enExample) |
| JP (2) | JP5944382B2 (enExample) |
| CN (2) | CN103079594B (enExample) |
| CA (1) | CA2801917C (enExample) |
| CY (1) | CY1120664T1 (enExample) |
| DK (1) | DK2575884T3 (enExample) |
| ES (1) | ES2685607T3 (enExample) |
| HR (1) | HRP20181598T1 (enExample) |
| HU (1) | HUE039740T2 (enExample) |
| LT (1) | LT2575884T (enExample) |
| MX (1) | MX2012014080A (enExample) |
| PL (1) | PL2575884T3 (enExample) |
| PT (1) | PT2575884T (enExample) |
| RS (1) | RS57543B1 (enExample) |
| SI (1) | SI2575884T1 (enExample) |
| SM (1) | SMT201800428T1 (enExample) |
| WO (1) | WO2011153477A2 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| DE122004000004I1 (de) | 1996-02-09 | 2004-08-12 | Abott Biotechnology Ltd | Humane Antikörper welche an Humanen TNFalpha binden. |
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| TWI439284B (zh) * | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| AU2006246721B2 (en) | 2005-05-16 | 2012-12-13 | Abbvie Biotechnology Ltd | Use of TNF inhibitor for treatment of erosive polyarthritis |
| CA2626804A1 (en) | 2005-11-01 | 2007-08-09 | Abbott Biotechnology Ltd. | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
| MX2008012896A (es) | 2006-04-05 | 2008-10-14 | Abbott Biotech Ltd | Purificacion de anticuerpos. |
| WO2007120656A2 (en) * | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
| WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| CN103316402A (zh) | 2006-06-30 | 2013-09-25 | 艾伯维生物技术有限公司 | 自动注射装置 |
| NZ576133A (en) | 2006-10-27 | 2012-10-26 | Abbott Biotech Ltd | Crystalline anti-htnfalpha antibodies |
| WO2008154543A2 (en) * | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| EP2173380A4 (en) * | 2007-07-13 | 2011-08-31 | Abbott Biotech Ltd | METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER |
| WO2009020654A1 (en) * | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| NZ622583A (en) * | 2007-11-30 | 2015-08-28 | Abbvie Biotechnology Ltd | Protein formulations and methods of making same |
| HUE039740T2 (hu) * | 2010-06-03 | 2019-01-28 | Abbvie Biotechnology Ltd | Alkalmazások és készítmények hidradenitis suppurativa (HS) kezelésére |
| PT2582391T (pt) | 2010-06-18 | 2019-01-11 | Xbiotech Inc | Tratamento da artrite |
| RU2013110030A (ru) | 2010-08-23 | 2014-09-27 | ИксБиотеч, Инк. | Лечение неопластических заболеваний |
| AU2011325974B2 (en) | 2010-11-11 | 2016-10-27 | Abbvie Biotechnology Ltd. | Improved high concentration anti-TNFalpha antibody liquid formulations |
| EP3187216B1 (en) | 2011-01-24 | 2019-08-21 | AbbVie Biotechnology Ltd. | Automatic injection devices having overmolded gripping surfaces |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| HK1211981A1 (en) | 2012-09-02 | 2016-06-03 | Abbvie Inc. | Methods to control protein heterogeneity |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| WO2015057910A1 (en) | 2013-10-16 | 2015-04-23 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| US10696735B2 (en) | 2015-01-21 | 2020-06-30 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
| EP3411401A1 (en) | 2016-02-03 | 2018-12-12 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| SG10202001787QA (en) | 2016-06-02 | 2020-04-29 | Abbvie Inc | Glucocorticoid receptor agonist and immunoconjugates thereof |
| DK3538118T3 (da) | 2016-11-11 | 2021-05-25 | Sjaellands Univ Dermatologisk Afdeling | Levende saprofytbakterier til anvendelse til behandling af hidradenitis suppurativa |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR20190117579A (ko) | 2017-02-16 | 2019-10-16 | 엑스바이오테크, 인크. | 화농성 한선염의 치료 |
| US20200277369A1 (en) * | 2017-11-20 | 2020-09-03 | Novartis Ag | Method of treating hidradentitis suppurativa with il-17 antagonists |
| CA3082356A1 (en) | 2017-12-01 | 2019-06-06 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019130215A1 (en) * | 2017-12-27 | 2019-07-04 | To Pharmaceuticals Llc | Cannabis compositions for the treatment of inflammatory skin disorders |
| WO2019177888A1 (en) | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis |
| TWI737000B (zh) * | 2018-10-22 | 2021-08-21 | 美商美國禮來大藥廠 | 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體 |
| EP3880210A1 (en) | 2018-11-15 | 2021-09-22 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| MX2021015995A (es) | 2019-06-28 | 2022-03-11 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| CN115052627A (zh) | 2019-12-17 | 2022-09-13 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| EP4167728A4 (en) * | 2020-06-17 | 2024-09-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP7812364B2 (ja) | 2020-07-17 | 2026-02-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体 |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| CA3202360A1 (en) | 2020-12-30 | 2022-07-07 | Nello Mainolfi | Irak degraders and uses thereof |
| US11773103B2 (en) | 2021-02-15 | 2023-10-03 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| KR20240023123A (ko) * | 2021-06-22 | 2024-02-20 | 노파르티스 아게 | 화농성 한선염의 치료에 사용하기 위한 이중특이적 항체 |
| CA3236265A1 (en) | 2021-10-29 | 2023-05-04 | William Leong | Irak4 degraders and synthesis thereof |
| US12091411B2 (en) | 2022-01-31 | 2024-09-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| KR20250031013A (ko) * | 2023-08-23 | 2025-03-06 | (주)셀트리온 | TNFα 관련 질환을 치료하는 방법 |
| TW202535928A (zh) * | 2024-01-03 | 2025-09-16 | 美商艾伯維有限公司 | 治療化膿性汗腺炎之方法 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| US5959087A (en) | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
| US6448380B2 (en) | 1989-08-07 | 2002-09-10 | Peptech Limited | Tumor necrosis factor antibodies |
| AU630497B2 (en) | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233769D1 (de) | 1991-03-01 | 2009-09-24 | Dyax Corp | Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon |
| EP1097945B1 (en) | 1991-03-18 | 2007-07-04 | New York University | Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| US5605923A (en) | 1992-04-02 | 1997-02-25 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| JPH07504203A (ja) | 1992-09-15 | 1995-05-11 | イミュネックス・コーポレーション | 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法 |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| DE122004000004I1 (de) | 1996-02-09 | 2004-08-12 | Abott Biotechnology Ltd | Humane Antikörper welche an Humanen TNFalpha binden. |
| US6177077B1 (en) | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| US6537549B2 (en) | 1999-02-24 | 2003-03-25 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| JP4731793B2 (ja) | 2000-12-28 | 2011-07-27 | アルセア テクノロジーズ インコーポレイテッド | 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法 |
| US20030012786A1 (en) | 2001-05-25 | 2003-01-16 | Teoh Leah S. | Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients |
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US20030161828A1 (en) | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
| US20040009172A1 (en) | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| AR040603A1 (es) | 2002-07-19 | 2005-04-13 | Abbott Lab S A | El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos |
| US20090280065A1 (en) | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| CN1988918A (zh) * | 2004-04-09 | 2007-06-27 | 艾博特生物技术有限公司 | 用于治疗TNFα－相关病症的多变剂量方案 |
| TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| EP1807111A4 (en) | 2004-10-08 | 2009-05-27 | Abbott Biotech Ltd | SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV) |
| AU2006246721B2 (en) * | 2005-05-16 | 2012-12-13 | Abbvie Biotechnology Ltd | Use of TNF inhibitor for treatment of erosive polyarthritis |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| CA2626804A1 (en) | 2005-11-01 | 2007-08-09 | Abbott Biotechnology Ltd. | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
| MX2008012896A (es) | 2006-04-05 | 2008-10-14 | Abbott Biotech Ltd | Purificacion de anticuerpos. |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| WO2007120656A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
| US20090317399A1 (en) | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
| WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| CN103316402A (zh) | 2006-06-30 | 2013-09-25 | 艾伯维生物技术有限公司 | 自动注射装置 |
| BRPI0716762A2 (pt) | 2006-09-13 | 2013-09-24 | Abbott Lab | melhorias da cultura celular |
| NZ576133A (en) | 2006-10-27 | 2012-10-26 | Abbott Biotech Ltd | Crystalline anti-htnfalpha antibodies |
| WO2008150491A2 (en) | 2007-05-31 | 2008-12-11 | Abbott Laboratories | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS |
| EP2152318A4 (en) | 2007-06-01 | 2011-12-07 | Abbott Biotech Ltd | COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE |
| WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| EP2173380A4 (en) | 2007-07-13 | 2011-08-31 | Abbott Biotech Ltd | METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER |
| WO2009020654A1 (en) | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| WO2009032128A1 (en) | 2007-08-28 | 2009-03-12 | Abbott Biotechnology Ltd. | Compositions and methods comprising binding proteins for adalimumab |
| NZ622583A (en) | 2007-11-30 | 2015-08-28 | Abbvie Biotechnology Ltd | Protein formulations and methods of making same |
| EP2225276B1 (en) * | 2007-12-31 | 2014-04-23 | Bayer Intellectual Property GmbH | Antibodies to tnf alpha |
| CN101965514A (zh) | 2008-01-03 | 2011-02-02 | 艾博特生物技术有限公司 | 预测化合物在治疗银屑病中的长期功效 |
| NZ600979A (en) | 2008-01-15 | 2014-01-31 | Abbott Lab | Improved mammalian expression vectors and uses thereof |
| BRPI0907186A2 (pt) | 2008-01-15 | 2015-07-14 | Abbott Gmbh & Co Kg | Composições proteicas pulverizadas e métodos para sua produção |
| US20100040630A1 (en) | 2008-03-24 | 2010-02-18 | Aake Elden | Methods and compositions for treating bone loss |
| CN101684156B (zh) * | 2008-09-27 | 2011-12-28 | 苏州工业园区晨健抗体组药物开发有限公司 | 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用 |
| CN102458517B (zh) | 2009-04-29 | 2014-07-23 | 阿布维生物技术有限公司 | 自动注射装置 |
| RU2560701C2 (ru) | 2009-05-04 | 2015-08-20 | Эббви Байотекнолоджи Лтд. | Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| EP2531613A2 (en) | 2010-02-02 | 2012-12-12 | Abbott Biotechnology Ltd. | Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor |
| HUE039740T2 (hu) * | 2010-06-03 | 2019-01-28 | Abbvie Biotechnology Ltd | Alkalmazások és készítmények hidradenitis suppurativa (HS) kezelésére |
-
2011
- 2011-06-03 HU HUE11790495A patent/HUE039740T2/hu unknown
- 2011-06-03 CN CN201180035021.1A patent/CN103079594B/zh not_active Expired - Fee Related
- 2011-06-03 DK DK11790495.3T patent/DK2575884T3/en active
- 2011-06-03 JP JP2013513388A patent/JP5944382B2/ja active Active
- 2011-06-03 EP EP11790495.3A patent/EP2575884B1/en active Active
- 2011-06-03 CN CN201510560983.9A patent/CN105056232A/zh active Pending
- 2011-06-03 WO PCT/US2011/039135 patent/WO2011153477A2/en not_active Ceased
- 2011-06-03 CA CA2801917A patent/CA2801917C/en active Active
- 2011-06-03 LT LTEP11790495.3T patent/LT2575884T/lt unknown
- 2011-06-03 RS RS20180883A patent/RS57543B1/sr unknown
- 2011-06-03 HR HRP20181598TT patent/HRP20181598T1/hr unknown
- 2011-06-03 PT PT11790495T patent/PT2575884T/pt unknown
- 2011-06-03 US US13/153,131 patent/US8747854B2/en active Active
- 2011-06-03 ES ES11790495.3T patent/ES2685607T3/es active Active
- 2011-06-03 PL PL11790495T patent/PL2575884T3/pl unknown
- 2011-06-03 MX MX2012014080A patent/MX2012014080A/es active IP Right Grant
- 2011-06-03 SI SI201131570T patent/SI2575884T1/sl unknown
- 2011-06-04 SM SM20180428T patent/SMT201800428T1/it unknown
-
2014
- 2014-05-28 US US14/289,115 patent/US9334320B2/en active Active
-
2016
- 2016-05-06 US US15/148,089 patent/US20170101465A1/en not_active Abandoned
- 2016-05-24 JP JP2016103023A patent/JP2016193916A/ja active Pending
-
2018
- 2018-09-07 CY CY181100938T patent/CY1120664T1/el unknown